Suzhou Novoprotein Scientific Co. Ltd. A
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular … Read more
Suzhou Novoprotein Scientific Co. Ltd. A (688137) - Net Assets
Latest net assets as of June 2025: CN¥2.08 Billion CNY
Based on the latest financial reports, Suzhou Novoprotein Scientific Co. Ltd. A (688137) has net assets worth CN¥2.08 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.20 Billion) and total liabilities (CN¥116.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.08 Billion |
| % of Total Assets | 94.7% |
| Annual Growth Rate | 112.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 212.61 |
Suzhou Novoprotein Scientific Co. Ltd. A - Net Assets Trend (2020–2024)
This chart illustrates how Suzhou Novoprotein Scientific Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Suzhou Novoprotein Scientific Co. Ltd. A (2020–2024)
The table below shows the annual net assets of Suzhou Novoprotein Scientific Co. Ltd. A from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.10 Billion | -3.97% |
| 2023-12-31 | CN¥2.19 Billion | -0.53% |
| 2022-12-31 | CN¥2.20 Billion | +511.57% |
| 2021-12-31 | CN¥359.77 Million | +248.97% |
| 2020-12-31 | CN¥103.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Suzhou Novoprotein Scientific Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 29.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥60.02 Million | 2.86% |
| Other Components | CN¥2.04 Billion | 97.14% |
| Total Equity | CN¥2.10 Billion | 100.00% |
Suzhou Novoprotein Scientific Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Suzhou Novoprotein Scientific Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Randon S.A. Implementos e Participações
SA:RAPT3
|
$145.39 Million |
|
Taigen Biopharmaceuticals Holdings Ltd
TWO:4157
|
$145.40 Million |
|
Man Industries (India) Limited
NSE:MANINDS
|
$145.44 Million |
|
Deep Value Driller AS
OL:DVD
|
$145.46 Million |
|
Savencia SA
PINK:BNGRF
|
$145.31 Million |
|
LITALICO Inc.
F:9N0
|
$145.22 Million |
|
Kung Sing Engineering Corp
TW:5521
|
$145.21 Million |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
$145.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Suzhou Novoprotein Scientific Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,188,489,498 to 2,101,667,720, a change of -86,821,778 (-4.0%).
- Net loss of 54,416,282 reduced equity.
- Dividend payments of 35,087,720 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-54.42 Million | -2.59% |
| Dividends Paid | CN¥35.09 Million | -1.67% |
| Other Changes | CN¥2.68 Million | +0.13% |
| Total Change | CN¥- | -3.97% |
Book Value vs Market Value Analysis
This analysis compares Suzhou Novoprotein Scientific Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.17x to 1.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥1.96 | CN¥41.47 | x |
| 2021-12-31 | CN¥6.84 | CN¥41.47 | x |
| 2022-12-31 | CN¥31.35 | CN¥41.47 | x |
| 2023-12-31 | CN¥31.19 | CN¥41.47 | x |
| 2024-12-31 | CN¥29.95 | CN¥41.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Suzhou Novoprotein Scientific Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.66%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.06x
- Recent ROE (-2.59%) is below the historical average (24.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 80.55% | 46.18% | 0.97x | 1.79x | CN¥72.74 Million |
| 2021 | 41.42% | 43.58% | 0.67x | 1.43x | CN¥113.03 Million |
| 2022 | 4.12% | 34.29% | 0.11x | 1.06x | CN¥-129.30 Million |
| 2023 | 0.59% | 8.38% | 0.07x | 1.05x | CN¥-206.01 Million |
| 2024 | -2.59% | -42.66% | 0.06x | 1.06x | CN¥-264.58 Million |
Industry Comparison
This section compares Suzhou Novoprotein Scientific Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Suzhou Novoprotein Scientific Co. Ltd. A (688137) | CN¥2.08 Billion | 80.55% | 0.06x | $145.38 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |